{
    "Rank": 942,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00268346",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "CCF5538"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "P30CA043703",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA043703"
                        },
                        {
                            "SecondaryId": "CCF-5538",
                            "SecondaryIdType": "Other Identifier",
                            "SecondaryIdDomain": "Cleveland Clinic IRB"
                        },
                        {
                            "SecondaryId": "ZENECA-1839IL/0234"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Case Comprehensive Cancer Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer",
                "OfficialTitle": "A Phase II Trial of ZD1839 (IRESSA\u00ae) for Patients With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction"
            },
            "StatusModule": {
                "StatusVerifiedDate": "December 2015",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "October 2005"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "January 2011",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "August 2011",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "December 20, 2005",
                "StudyFirstSubmitQCDate": "December 20, 2005",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "December 22, 2005",
                    "StudyFirstPostDateType": "Estimate"
                },
                "ResultsFirstSubmitDate": "October 27, 2011",
                "ResultsFirstSubmitQCDate": "February 14, 2012",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "March 16, 2012",
                    "ResultsFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "December 4, 2015",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "January 5, 2016",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "David Adelstein, MD",
                    "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
                    "ResponsiblePartyInvestigatorAffiliation": "Case Comprehensive Cancer Center"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Case Comprehensive Cancer Center",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.\n\nPURPOSE: This phase II trial is studying how well gefitinib works in treating patients with recurrent or metastatic esophageal or gastroesophageal junction cancer.",
                "DetailedDescription": "OBJECTIVES:\n\nPrimary\n\nExplore the activity of single agent gefitinib, in terms of response rate, in a patient population with recurrent or metastatic esophageal or gastroesophageal junction cancer.\n\nSecondary\n\nAssess the toxicity of this drug in these patients.\n\nOUTLINE: Patients are stratified according to prior treatment (yes vs no).\n\nPatients receive oral gefitinib once daily for at least 8 weeks in the absence of disease progression or unacceptable toxicity.\n\nAfter completion of study treatment, patients are followed periodically for survival.\n\nPROJECTED ACCRUAL: A total of 76 patients will be accrued for this study."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Esophageal Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "adenocarcinoma of the esophagus",
                        "recurrent esophageal cancer",
                        "squamous cell carcinoma of the esophagus",
                        "stage IV esophageal cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "58",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "ZD1839",
                            "ArmGroupType": "Experimental",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: ZD1839"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "ZD1839",
                            "InterventionDescription": "ZD1839 treatment will be taken once a day PO, every day about the same time",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "ZD1839"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "IRESSA\u00ae",
                                    "Gefitinib"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "The Number of Patients With Complete or Partial Response Rate of Single Agent ZD1839 in a Patient Population With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction, Using the RECIST 1.0 Criteria.",
                            "PrimaryOutcomeDescription": "The overall response is the number of patients with the best response recorded in measurable disease (target lesions) from start to disease progression.Complete response is the number of patients with the disappearance of all target lesions. Partial response is the number of patients with larger than or equal to 30% decrease in sum of the longest diameters from baseline. Progressive disease is larger than or equal to 20% increase in sum of the longest diameters over the smallest sum observed or appearance of new lesions. Stable disease is neither PR nor PD criteria met.",
                            "PrimaryOutcomeTimeFrame": "at 8 weeks after initiation of treatment"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nPathologically confirmed squamous cell carcinoma, adenocarcinoma, or large-cell undifferentiated carcinoma of the esophagus or gastroesophageal junction\n\nPatients must have disease that is either metastatic (i.e., M1b by the definitions of the American Joint Committee on Cancer 1997 staging system) or recurrent after definitive therapy, and must be considered incurable by conventional treatments\nPatients with small cell, or mixed small cell/non-small-cell histology are ineligible\nPatients with lymphoma or sarcoma are also ineligible\n\nDisease must be measurable in at least one dimension by physical exam, x-ray, CT scan or MRI, ultrasound, or endoscopy\n\nMeasurable disease can be a previously irradiated lesion if disease growth has been documented in the lesion since completion of radiation therapy\nAn elevation in carcinoembryonic antigen (CEA) is not sufficient to use by itself in response assessment\n\nPATIENT CHARACTERISTICS:\n\nECOG Performance Status 0-1\nWBC \u2265 3,000/mm^3\nPlatelet count \u2265 100,000/mm^3\nCreatinine \u2264 2.0 mg/dL\nAlkaline phosphatase and AST < twice normal\nBilirubin < twice normal\nCalcium normal\nNo known severe hypersensitivity to study drug or any of its excipients\nNo clinical evidence of any other uncontrolled malignancy except adequately treated basal or squamous cell skin cancer or in situ cervical cancer\nPregnant or nursing women are ineligible\nFertile patients must use effective contraception\nNo evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)\n\nNo evidence of clinically active interstitial lung disease\n\nPatients with chronic stable radiographic changes who are asymptomatic need not be excluded\n\nPRIOR CONCURRENT THERAPY:\n\nPatients may not have received more than one previous systemic treatment regimen\n\nSystemic treatment may have been given as part of definitive (adjuvant, neoadjuvant, concurrent, or sequential) management or for metastatic or recurrent disease\nPreviously untreated patients are also eligible\nNo previous treatment with study drug or any other epidermal growth factor receptor (EGFR) antagonists\nMore than 30 days since prior treatment with a non-approved or investigational drug\nAt least 4 weeks must have elapsed since any surgery, radiation therapy, or chemotherapy administration\nRecovered from previous oncologic or other major surgery\nNo concurrent barbiturates (e.g., phenytoin), carbamazepine, rifampicin, phenobarbital or Hypericum perforatum (St. John's wort)\nNo concurrent surgery, radiation therapy, hormonal therapy, or other chemotherapy",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "David J. Adelstein, MD",
                            "OverallOfficialAffiliation": "Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center",
                            "OverallOfficialRole": "Study Chair"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center",
                            "LocationCity": "Cleveland",
                            "LocationState": "Ohio",
                            "LocationZip": "44195",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowRecruitmentDetails": "Subjects recruited from April 2003 to January 2010 from medical clinic",
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "No Prior Chem Therapy",
                            "FlowGroupDescription": "Patients receive oral gefitinib once daily for at least 8 weeks in the absence of disease progression or unacceptable toxicity."
                        },
                        {
                            "FlowGroupId": "FG001",
                            "FlowGroupTitle": "Prior Chemotherapy",
                            "FlowGroupDescription": "Patients may not have received more than one previous systemic treatment regimen. Systemic treatment may have been given as part of definitive (adjuvant, neoadjuvant, concurrent, or sequential) management or for metastatic or recurrent disease. Patients receive oral gefitinib once daily for at least 8 weeks in the absence of disease progression or unacceptable toxicity."
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "18"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "40"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "Started Treatment",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "18"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "40"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "18"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "37"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "0"
                                                },
                                                {
                                                    "FlowAchievementGroupId": "FG001",
                                                    "FlowAchievementNumSubjects": "3"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "FlowDropWithdrawList": {
                                "FlowDropWithdraw": [
                                    {
                                        "FlowDropWithdrawType": "Adverse Event",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "0"
                                                },
                                                {
                                                    "FlowReasonGroupId": "FG001",
                                                    "FlowReasonNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Death",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "0"
                                                },
                                                {
                                                    "FlowReasonGroupId": "FG001",
                                                    "FlowReasonNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Withdrawal by Subject",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "0"
                                                },
                                                {
                                                    "FlowReasonGroupId": "FG001",
                                                    "FlowReasonNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "No Prior Chem Therapy",
                            "BaselineGroupDescription": "Patients receive oral gefitinib once daily for at least 8 weeks in the absence of disease progression or unacceptable toxicity."
                        },
                        {
                            "BaselineGroupId": "BG001",
                            "BaselineGroupTitle": "Prior Chemotherapy",
                            "BaselineGroupDescription": "Patients may not have received more than one previous systemic treatment regimen. Systemic treatment may have been given as part of definitive (adjuvant, neoadjuvant, concurrent, or sequential) management or for metastatic or recurrent disease. Patients receive oral gefitinib once daily for at least 8 weeks in the absence of disease progression or unacceptable toxicity."
                        },
                        {
                            "BaselineGroupId": "BG002",
                            "BaselineGroupTitle": "Total",
                            "BaselineGroupDescription": "Total of all reporting groups"
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "18"
                                    },
                                    {
                                        "BaselineDenomCountGroupId": "BG001",
                                        "BaselineDenomCountValue": "40"
                                    },
                                    {
                                        "BaselineDenomCountGroupId": "BG002",
                                        "BaselineDenomCountValue": "58"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Continuous",
                            "BaselineMeasureParamType": "Median",
                            "BaselineMeasureDispersionType": "Full Range",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "66",
                                                                "BaselineMeasurementLowerLimit": "45",
                                                                "BaselineMeasurementUpperLimit": "82"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "58",
                                                                "BaselineMeasurementLowerLimit": "33",
                                                                "BaselineMeasurementUpperLimit": "73"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "60",
                                                                "BaselineMeasurementLowerLimit": "33",
                                                                "BaselineMeasurementUpperLimit": "82"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "3"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "7"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "10"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "15"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG001",
                                                                "BaselineMeasurementValue": "33"
                                                            },
                                                            {
                                                                "BaselineMeasurementGroupId": "BG002",
                                                                "BaselineMeasurementValue": "48"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "The Number of Patients With Complete or Partial Response Rate of Single Agent ZD1839 in a Patient Population With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction, Using the RECIST 1.0 Criteria.",
                            "OutcomeMeasureDescription": "The overall response is the number of patients with the best response recorded in measurable disease (target lesions) from start to disease progression.Complete response is the number of patients with the disappearance of all target lesions. Partial response is the number of patients with larger than or equal to 30% decrease in sum of the longest diameters from baseline. Progressive disease is larger than or equal to 20% increase in sum of the longest diameters over the smallest sum observed or appearance of new lesions. Stable disease is neither PR nor PD criteria met.",
                            "OutcomeMeasurePopulationDescription": "All patients enrolled were analyzed",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "participants",
                            "OutcomeMeasureTimeFrame": "at 8 weeks after initiation of treatment",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "No Prior Therapy",
                                        "OutcomeGroupDescription": "All patients will receive oral ZD1839 250 mg daily. Pill counts will be conducted at every visit to monitor compliance. Treatment will be continued for a minimum of 8 weeks."
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Prior Chemotherapy",
                                        "OutcomeGroupDescription": "All patients will receive oral ZD1839 250 mg daily. Pill counts will be conducted at every visit to monitor compliance. Treatment will be continued for a minimum of 8 weeks."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "18"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "40"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1",
                                                                "OutcomeMeasurementLowerLimit": "0.1",
                                                                "OutcomeMeasurementUpperLimit": "27.3"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "3",
                                                                "OutcomeMeasurementLowerLimit": "1.6",
                                                                "OutcomeMeasurementUpperLimit": "20.4"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeAnalysisList": {
                                "OutcomeAnalysis": [
                                    {
                                        "OutcomeAnalysisGroupIdList": {
                                            "OutcomeAnalysisGroupId": [
                                                "OG000",
                                                "OG001"
                                            ]
                                        },
                                        "OutcomeAnalysisGroupDescription": "In patients with prior chemotherapy, >25% response indicates efficacy and <10% indicates lack of efficacy. In patients with no prior chemotherapy, >45% response indicates efficacy and <25% indicates lack of efficacy. Using a 5% significance level, the study was designed to have 80% power to test each hypothesis.",
                                        "OutcomeAnalysisTestedNonInferiority": "No",
                                        "OutcomeAnalysisNonInferiorityType": "Superiority or Other",
                                        "OutcomeAnalysisPValue": "<0.05",
                                        "OutcomeAnalysisStatisticalMethod": "binomial test for a single proportion",
                                        "OutcomeAnalysisParamType": "percentage response",
                                        "OutcomeAnalysisParamValue": "6.9",
                                        "OutcomeAnalysisCIPctValue": "95",
                                        "OutcomeAnalysisCINumSides": "2-Sided"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "0",
                "EventsTimeFrame": "From study start to 30 days after final treatment",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "No Prior Chem Therapy",
                            "EventGroupDescription": "Patients receive oral gefitinib once daily for at least 8 weeks in the absence of disease progression or unacceptable toxicity.",
                            "EventGroupSeriousNumAffected": "4",
                            "EventGroupSeriousNumAtRisk": "18",
                            "EventGroupOtherNumAffected": "13",
                            "EventGroupOtherNumAtRisk": "18"
                        },
                        {
                            "EventGroupId": "EG001",
                            "EventGroupTitle": "Prior Chemotherapy",
                            "EventGroupDescription": "Patients may not have received more than one previous systemic treatment regimen. Systemic treatment may have been given as part of definitive (adjuvant, neoadjuvant, concurrent, or sequential) management or for metastatic or recurrent disease. Patients receive oral gefitinib once daily for at least 8 weeks in the absence of disease progression or unacceptable toxicity.",
                            "EventGroupSeriousNumAffected": "4",
                            "EventGroupSeriousNumAtRisk": "40",
                            "EventGroupOtherNumAffected": "33",
                            "EventGroupOtherNumAtRisk": "40"
                        }
                    ]
                },
                "SeriousEventList": {
                    "SeriousEvent": [
                        {
                            "SeriousEventTerm": "death",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "0",
                                        "SeriousEventStatsNumAffected": "0",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    },
                                    {
                                        "SeriousEventStatsGroupId": "EG001",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "40"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "hospitalization",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (2.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "4",
                                        "SeriousEventStatsNumAffected": "4",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    },
                                    {
                                        "SeriousEventStatsGroupId": "EG001",
                                        "SeriousEventStatsNumEvents": "3",
                                        "SeriousEventStatsNumAffected": "3",
                                        "SeriousEventStatsNumAtRisk": "40"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "OtherEventList": {
                    "OtherEvent": [
                        {
                            "OtherEventTerm": "Anorexia",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "18"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "40"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Diarrhea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "18"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "20",
                                        "OtherEventStatsNumAtRisk": "40"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dry Skin",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "18"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "40"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dysphagia",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "18"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "40"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fatigue",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "18"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "40"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Mucositis/Stomatitis",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "0",
                                        "OtherEventStatsNumAtRisk": "18"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "40"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Nausea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "18"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "40"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Rash",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (2.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "8",
                                        "OtherEventStatsNumAtRisk": "18"
                                    },
                                    {
                                        "OtherEventStatsGroupId": "EG001",
                                        "OtherEventStatsNumAffected": "31",
                                        "OtherEventStatsNumAtRisk": "40"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "Yes"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "David Adelstein MD",
                    "PointOfContactOrganization": "Cleveland Clinic Taussig Cancer Institute",
                    "PointOfContactEMail": "adelstd@ccf.org",
                    "PointOfContactPhone": "216-444-9310"
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000004938",
                            "ConditionMeshTerm": "Esophageal Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000005770",
                            "ConditionAncestorTerm": "Gastrointestinal Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000004067",
                            "ConditionAncestorTerm": "Digestive System Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000006258",
                            "ConditionAncestorTerm": "Head and Neck Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000004066",
                            "ConditionAncestorTerm": "Digestive System Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000004935",
                            "ConditionAncestorTerm": "Esophageal Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005767",
                            "ConditionAncestorTerm": "Gastrointestinal Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M11997",
                            "ConditionBrowseLeafName": "Neoplasm Metastasis",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5224",
                            "ConditionBrowseLeafName": "Carcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M3275",
                            "ConditionBrowseLeafName": "Adenocarcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M7778",
                            "ConditionBrowseLeafName": "Esophageal Neoplasms",
                            "ConditionBrowseLeafAsFound": "Esophageal Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M14540",
                            "ConditionBrowseLeafName": "Recurrence",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5240",
                            "ConditionBrowseLeafName": "Carcinoma, Squamous Cell",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M1733",
                            "ConditionBrowseLeafName": "Esophageal Squamous Cell Carcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8576",
                            "ConditionBrowseLeafName": "Gastrointestinal Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6946",
                            "ConditionBrowseLeafName": "Digestive System Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M9038",
                            "ConditionBrowseLeafName": "Head and Neck Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6945",
                            "ConditionBrowseLeafName": "Digestive System Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8573",
                            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M7775",
                            "ConditionBrowseLeafName": "Esophageal Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T2141",
                            "ConditionBrowseLeafName": "Esophageal Cancer",
                            "ConditionBrowseLeafAsFound": "Esophageal Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC06",
                            "ConditionBrowseBranchName": "Digestive System Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000077156",
                            "InterventionMeshTerm": "Gefitinib"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000047428",
                            "InterventionAncestorTerm": "Protein Kinase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M1679",
                            "InterventionBrowseLeafName": "Gefitinib",
                            "InterventionBrowseLeafAsFound": "Supportive",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M25510",
                            "InterventionBrowseLeafName": "Protein Kinase Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}